ArticleIndian journal of surgical oncology2020
Classification of Leptomeningeal Metastases from Solid Organ Malignancies and Clinical Outcomes: Series from a Cancer Research Centre.
Article in Indian journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastases (LMs) are a critical neurological manifestation of solid organ malignancies. Early diagnosis and prompt treatment is necessary to improve outcomes. We classified LM on the basis of cytological or histological and imaging studies. A total of 14 patients of LM from solid organ malignancies diagnosed between July 2016 and December 2018 were included in the series. LM was classified based on cerebrospinal fluid (CSF) cytology and magnetic resonance imaging (MRI) findings. Survival outcomes were noted. LM from carcinoma of breast and lung accounted for most of the cases. Type I LM was seen in 12 patients while 2 accounted for type II LM. Median overall survival (OS) was 40.5 days. Newer-generation tyrosine kinase inhibitor (TKI) therapy seems promising in the treatment of LM. Classification of LM based on cytology/histology and imaging findings allows early diagnosis and treatment. Newer-generation TKIs should be used for the treatment of LM if indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.